Showing 81-90 of 3069 results for "".
Connective Tissue Disorders Update 2025: Dr. Vleugels
https://practicaldermatology.com/programs/practical-dermatology/connective-tissue-disorders-update-2025-dr-vleugels/32673/Ruth Ann Vleugels, MD, PhD, recaps her presentation, "Connective Tissue Disorders Update 2025" at Maui Derm 2025. Dr. Vleugels discussed a new therapeutic for systemic lupus, a new FDA-approved option for dermatomyositis, JAK inhibitors, and more.Dermwire TV Extra: The Global Access to Skin Health Observatory
https://practicaldermatology.com/series/dermwire-tv/global-access-skin-health-observatory/29873/Esther Freeman, MD, PhD, Director of Global Health Dermatology at Massachusetts General Hospital and Harvard Medical School, and Vice Chair of the International Foundation of Dermatology with the International League of Dermatological Societies (ILDS), talks with Practical Dermatology about her workSkin of Color Session: Dr. Harris
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/skin-of-color-session-dr-harris/32683/John E. Harris, MD, PhD, summarizes his vitiligo talk from the "Skin of Color Session" at Maui Derm 2025, during which he covered new therapeutic options for vitiligo as well as promising drugs in the pipeline and why they could be so impactful.Advances in PsO: Targeting IL-23
https://practicaldermatology.com/conferences/aad-summer-2021/advances-in-pso-targeting-il-23/19974/George Han, MD, PhD reviews the latest data available on IL-23 inhibitors for the treatment of psoriasis. He discusses the specific benefits of guselkumab, tildrakizumab, and risankizumab and shares insights about how they fit into the overall psoriasis treatment arsenal.Targeting Senescent Cells
https://practicaldermatology.com/series/c-suite-chats/targeting-senescent-cells/35960/Rubedo Life Science CEO Frederick Beddingfield III, MD, PhD, FAAD, FACMS, talks about the importance of addressing aging and senescence, and his company's investigational drug that targets pathological senescent cells and surrounding tissues that drive inflammaging and chronic degenerative diseasesAn Exciting Year in Dermatology
https://practicaldermatology.com/topics/psoriasis/an-exciting-year-in-dermatology/19929/From new topicals to novel systemic agents, several treatments may be coming to the market in the next two years, while existing therapies may see label expansions. Bruce Strober, MD, PhD offers a look at new MOAs and the evidence for their use.FDA Approves Roflumilast for Seborrheic Dermatitis in Young Patients
https://practicaldermatology.com/topics/other-dermatitis/fda-approves-roflumilast-for-seborrheic-dermatitis-in-young-patients/20230/Patrick Burnett, MD, PhD, chief medical officer of Arcutis Biotherapeutics, talks with Practical Dermatology® about the first new treatment for seborrheic dermatitis in more than 20 years, their newly approved ZORYVE (roflumilast)Topical Foam, 0.3% for use in patients aged 9 years or older.Dr. Tsao, Dr. Friedlander Recap Biggest Developments for Maui Derm
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/dr-tsao-dr-friedlander-recap-biggest-developments-for-maui-derm/32913/The development of new therapeutics for dermatologic conditions in recent years has been so prolific that Hensin Tsao, MD, PhD, used a “Maui Journal of Medicine” theme for his conference-opening presentation at the Maui Derm Hawaii 2025 meeting in Maui, Hawaii.Dr. Anderson on New Tech That ‘Could be Revolutionary’ at Maui Derm
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/dr-anderson-on-new-tech-that-could-be-revolutionary-at-maui-derm/32921/In-vivo microscopy that will change how dermatologists practice and potentially revolutionary drug delivery systems were among the technologies highlighted by R. Rox Anderson, MD, PhD, during “Innovation in Dermatology 2025: A Look Into the Future of Dermatology” at the Maui Derm Hawaii 2025 meetingItching for Answers: Understanding and Treating Pruritus
https://practicaldermatology.com/topics/general-topics/itching-for-answers-understanding-and-treating-pruritus/18493/Since childhood, when he was affected by eczema and associated pruritus, Ethan Lerner, MD, PhD has been fascinated by itch, its causes, and its potential treatments. In this edition of Benchside Dispatches, he offers a fresh look at the latest research on pruritus and the challenges facing scientist